New Stock Update: Kangnuo Biotech's Hong Kong IPO Prospectus Expires

Stock News

2 hours ago

The prospectus submitted by Kangnuo Biotech Pharmaceutical Co., Ltd (referred to as Kangnuo Biotech) for its Hong Kong IPO on January 25, 2026, has expired after six months, on July 25, 2026. At the time of filing, SDIC Securities International acted as its sole sponsor.

According to the previous prospectus, Kangnuo Biotech is a biopharmaceutical enterprise focused on the research and development, drug production, and commercialization of mitochondrial medicine and health products.

The company specializes in studying diseases caused by mitochondrial dysfunction, dedicating its efforts to applying NAD+ in scientific research areas such as cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1144335647"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144335647\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144335647?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 07:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144335647","market":"other","top_or_hot":-1,"title":"New Stock Update: Kangnuo Biotech's Hong Kong IPO Prospectus Expires","media":"Stock News","content":"<p>The prospectus submitted by <b>Kangnuo Biotech Pharmaceutical Co., Ltd</b> (referred to as <b>Kangnuo Biotech</b>) for its Hong Kong IPO on January 25, 2026, has expired after six months, on July 25, 2026. At the time of filing, <b>SDIC Securities International</b> acted as its sole sponsor.<br><br>According to the previous prospectus, <b>Kangnuo Biotech</b> is a biopharmaceutical enterprise focused on the research and development, drug production, and commercialization of mitochondrial medicine and health products.<br><br>The company specializes in studying diseases caused by mitochondrial dysfunction, dedicating its efforts to applying NAD+ in scientific research areas such as cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Stock Update: Kangnuo Biotech's Hong Kong IPO Prospectus Expires</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Stock Update: Kangnuo Biotech's Hong Kong IPO Prospectus Expires\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-27 07:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The prospectus submitted by <b>Kangnuo Biotech Pharmaceutical Co., Ltd</b> (referred to as <b>Kangnuo Biotech</b>) for its Hong Kong IPO on January 25, 2026, has expired after six months, on July 25, 2026. At the time of filing, <b>SDIC Securities International</b> acted as its sole sponsor.<br><br>According to the previous prospectus, <b>Kangnuo Biotech</b> is a biopharmaceutical enterprise focused on the research and development, drug production, and commercialization of mitochondrial medicine and health products.<br><br>The company specializes in studying diseases caused by mitochondrial dysfunction, dedicating its efforts to applying NAD+ in scientific research areas such as cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REDS","symbol_name":"RPM Republican Senate ETF","start_time":0,"source_url":"","article_id":"1144335647","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144335647","pubTimestamp":1785107898,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The prospectus submitted by Kangnuo Biotech Pharmaceutical Co., Ltd (referred to as Kangnuo Biotech) for its Hong Kong IPO on January 25, 2026, has expired after six months, on July 25, 2026. At the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"REDS":"RPM Republican Senate ETF","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","BK4127":"投资银行业与经纪业","IPOS":"Renaissance International IPO ETF","KCE":"SPDR KBW Capital Markets ETF","FRHC":"Euronext CAC Health Care","KCAI":"KraneShares China Alpha Index ETF","BK4588":"碎股"},"translate_title":"新股更新：康诺生物香港IPO招股说明书到期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REDS":1,"VXUS":1,"KCAI":1,"IPOS":1,"KCE":1,"FRHC":1},"content_text":"The prospectus submitted by Kangnuo Biotech Pharmaceutical Co., Ltd (referred to as Kangnuo Biotech) for its Hong Kong IPO on January 25, 2026, has expired after six months, on July 25, 2026. At the time of filing, SDIC Securities International acted as its sole sponsor.According to the previous prospectus, Kangnuo Biotech is a biopharmaceutical enterprise focused on the research and development, drug production, and commercialization of mitochondrial medicine and health products.The company specializes in studying diseases caused by mitochondrial dysfunction, dedicating its efforts to applying NAD+ in scientific research areas such as cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}